Literature DB >> 10842013

Synaptic loss is accompanied by an increase in synaptic area in the dentate gyrus of aged human apolipoprotein E4 transgenic mice.

K Cambon1, H A Davies, M G Stewart.   

Abstract

To investigate the relationship between the three isoforms of apolipoprotein E (E2, E3 and E4) and the integrity of the synaptic circuitry in the dentate gyrus of the hippocampus, we have estimated the synapse per neuron ratio and mean apposition zone area per synapse at the electron microscope level in the dentate gyrus of apolipoprotein E knockout and human apolipoprotein E transgenic mice aged six to 24months. During ageing, only in human apolipoprotein E4 mice was there a decrease in synapse per neuron ratio, accompanied by an increase in synaptic size. When these mice were compared with human apolipoprotein E2, apolipoprotein E knockout and wild-type mice at old age, they displayed the lowest synapse per neuron ratio, but similar apposition zone area. In contrast, as in our previous study, aged apolipoprotein E knockout mice did not show any sign of synaptic degeneration. The functional consequences of such morphological changes remain to be determined. However, if such age-related loss of synapses occurred in the brain of Alzheimer apolipoprotein E4 patients, they might be additive to pathological processes and could contribute to greater cognitive impairment.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10842013     DOI: 10.1016/s0306-4522(00)00065-8

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  21 in total

1.  Selective effect of Apo e4 on CA3 and dentate in normal aging and Alzheimer's disease using high resolution MRI at 4 T.

Authors:  S G Mueller; N Schuff; S Raptentsetsang; J Elman; M W Weiner
Journal:  Neuroimage       Date:  2008-04-22       Impact factor: 6.556

2.  (-)-Phenserine and the prevention of pre-programmed cell death and neuroinflammation in mild traumatic brain injury and Alzheimer's disease challenged mice.

Authors:  Daniela Lecca; Miaad Bader; David Tweedie; Alexander F Hoffman; Yoo Jin Jung; Shin-Chang Hsueh; Barry J Hoffer; Robert E Becker; Chaim G Pick; Carl R Lupica; Nigel H Greig
Journal:  Neurobiol Dis       Date:  2019-07-08       Impact factor: 5.996

3.  Reduced hippocampal CA2, CA3, and dentate gyrus activity in asymptomatic people at genetic risk for Alzheimer's disease.

Authors:  Nanthia A Suthana; Allison Krupa; Markus Donix; Alison Burggren; Arne D Ekstrom; Michael Jones; Linda M Ercoli; Karen J Miller; Prabha Siddarth; Gary W Small; Susan Y Bookheimer
Journal:  Neuroimage       Date:  2009-12-18       Impact factor: 6.556

4.  Diet and age interactions with regards to cholesterol regulation and brain pathogenesis.

Authors:  Romina M Uranga; Jeffrey N Keller
Journal:  Curr Gerontol Geriatr Res       Date:  2010-04-11

Review 5.  Progress toward identification of protease activity involved in proteolysis of apolipoprotein e in human brain.

Authors:  Marcos A Marques; Phillip A Owens; Keith A Crutcher
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

6.  Apolipoprotein E-related neurotoxicity as a therapeutic target for Alzheimer's disease.

Authors:  Marcos A Marques; Keith A Crutcher
Journal:  J Mol Neurosci       Date:  2003       Impact factor: 3.444

Review 7.  Genetic vulnerability following traumatic brain injury: the role of apolipoprotein E.

Authors:  N Nathoo; R Chetty; J R van Dellen; G H Barnett
Journal:  Mol Pathol       Date:  2003-06

8.  Selective effect of age, Apo e4, and Alzheimer's disease on hippocampal subfields.

Authors:  Susanne G Mueller; Michael W Weiner
Journal:  Hippocampus       Date:  2009-06       Impact factor: 3.899

9.  Apolipoprotein E and cholesterol in aging and disease in the brain.

Authors:  Elena Posse de Chaves; Vasanthy Narayanaswami
Journal:  Future Lipidol       Date:  2008-10

Review 10.  Apolipoprotein E is a prime suspect, not just an accomplice, in Alzheimer's disease.

Authors:  Keith A Crutcher
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.